AviadoBio
London
About AviadoBio
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $113.8M
- Last round: Corporate Round (Oct 2024)
- Website: aviadobio.com
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/aviadobio-56038 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.